Cyclopharm (ASX:CYC) Float Percentage Of Total Shares Outstanding: 0.00% (As of Jun. 30, 2026)


ASX:CYC Cyclopharm Ltd ASX:CYC
46 GF Score
Price A$0.49
GF Value A$0.84
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cyclopharm Float Percentage Of Total Shares Outstanding?

Cyclopharm ASX:CYC -2.00% 46 Float Percentage Of Total Shares Outstanding is 0.00% as of Jun. 30, 2026. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cyclopharm's float shares is 0.00 Mil. Cyclopharm's total shares outstanding is 126.07 Mil. Cyclopharm's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cyclopharm's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cyclopharm's Institutional Ownership is 0.11%.

ASX:CYC
46GF Score
Cyclopharm Ltd ASX:CYC
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclopharm Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Cyclopharm's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/126.07
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
Cyclopharm (ASX:CYC) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Jun. 30, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Cyclopharm and its competitors.
Is Cyclopharm's Float Percentage Of Total Shares Outstanding too high?
Cyclopharm's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Float Percentage Of Total Shares Outstanding compare to MCK and CAH?
Cyclopharm's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Medical Distribution company?
A good Float Percentage Of Total Shares Outstanding depends on the Medical Distribution industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Cyclopharm and its competitors. Cyclopharm's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.49 — trading 41.7% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 0.00%. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.49 is trading 41.7% below its estimated GF Value™ of A$0.84. GuruFocus considers Cyclopharm to be Possible Value Trap.

Key valuation signals for ASX:CYC:

  • Float Percentage Of Total Shares Outstanding: 0.00%
  • GF Value™: A$0.84 vs. price of A$0.49 (41.7% below fair value)
  • GF Score™: 46/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyclopharm Business Description

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
46GF Score

Get the complete analysis for ASX:CYC

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.49
Price
A$0.84
GF Value